144 related articles for article (PubMed ID: 38485723)
1. PTCy versus ATG as graft-versus-host disease prophylaxis in mismatched unrelated stem cell transplantation.
Penack O; Abouqateb M; Peczynski C; Boreland W; Gülbas Z; Gedde-Dahl T; Castilla-Llorente C; Kröger N; Eder M; Rambaldi A; Bonifazi F; Blau IW; Stelljes M; Dreger P; Moiseev I; Schoemans H; Koenecke C; Peric Z
Blood Cancer J; 2024 Mar; 14(1):45. PubMed ID: 38485723
[TBL] [Abstract][Full Text] [Related]
2. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
Penack O; Abouqateb M; Peczynski C; Boreland W; Kröger N; Stelljes M; Gedde-Dahl T; Blau IW; Schroeder T; Salmenniemi U; Kulagin A; Peffault de Latour R; Mielke S; Zeiser R; Moiseev I; Schoemans H; Koenecke C; Peric Z
Leukemia; 2024 May; 38(5):1156-1163. PubMed ID: 38538862
[TBL] [Abstract][Full Text] [Related]
3. Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors.
Jorge AS; Suárez-Lledó M; Pereira A; Gutierrez G; Fernández-Avilés F; Rosiñol L; Llobet N; Solano T; Urbano-Ispízua Á; Rovira M; Martínez C
Biol Blood Marrow Transplant; 2018 Jun; 24(6):1196-1202. PubMed ID: 29410343
[TBL] [Abstract][Full Text] [Related]
4. The Benefits of the Post-Transplant Cyclophosphamide in Both Haploidentical and Mismatched Unrelated Donor Setting in Allogeneic Stem Cells Transplantation.
Dybko J; Sobczyk-Kruszelnicka M; Makuch S; Agrawal S; Dudek K; Giebel S; Gil L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982839
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of Antithymocyte Globulin-Post-Transplantation Cyclophosphamide-Cyclosporine-Based versus Antithymocyte Globulin-Based Prophylaxis for 10/10 HLA-Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation.
Salas MQ; Alfaro-Moya T; Atenafu EG; Datt Law A; Lam W; Pasic I; Novitzky-Basso I; Santos Carreira A; Chen C; Michelis FV; Gerbitz A; Howard Lipton J; Kim DDH; Kumar R; Mattsson J; Viswabandya A
Transplant Cell Ther; 2024 May; 30(5):536.e1-536.e13. PubMed ID: 38281592
[TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative, HLA-Mismatched Unrelated Peripheral Blood Transplantation with High-Dose Post-Transplantation Cyclophosphamide.
Rappazzo KC; Zahurak M; Bettinotti M; Ali SA; Ambinder AJ; Bolaños-Meade J; Borrello I; Dezern AE; Gladstone D; Gocke C; Fuchs E; Huff CA; Imus PH; Jain T; Luznik L; Rahmat L; Swinnen LJ; Wagner-Johnston N; Jones RJ; Ambinder RF
Transplant Cell Ther; 2021 Nov; 27(11):909.e1-909.e6. PubMed ID: 34425261
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
[TBL] [Abstract][Full Text] [Related]
8. Posttransplant cyclophosphamide-based anti-graft-vs-host disease prophylaxis in patients with acute lymphoblastic leukemia treated in complete remission with allogeneic hematopoietic cell transplantation from human leukocyte antigen-mismatched unrelated donors versus haploidentical donors: A study on behalf of the ALWP of the EBMT.
Nagler A; Labopin M; Arat M; Reményi P; Koc Y; Blaise D; Angelucci E; Vydra J; Kulagin A; Socié G; Rovira M; Sica S; Aljurf M; Gülbas Z; Kröger N; Brissot E; Peric Z; Giebel S; Ciceri F; Mohty M
Cancer; 2022 Nov; 128(22):3959-3968. PubMed ID: 36110063
[TBL] [Abstract][Full Text] [Related]
9. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
10. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation.
Mehta RS; Saliba RM; Chen J; Rondon G; Hammerstrom AE; Alousi A; Qazilbash M; Bashir Q; Ahmed S; Popat U; Hosing C; Khouri I; Shpall EJ; Champlin RE; Ciurea SO
Br J Haematol; 2016 May; 173(3):444-55. PubMed ID: 26947769
[TBL] [Abstract][Full Text] [Related]
11. Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.
Battipaglia G; Labopin M; Kröger N; Vitek A; Afanasyev B; Hilgendorf I; Schetelig J; Ganser A; Blaise D; Itälä-Remes M; Passweg JR; Bonifazi F; Finke J; Ruggeri A; Nagler A; Mohty M
Blood; 2019 Sep; 134(11):892-899. PubMed ID: 31270102
[TBL] [Abstract][Full Text] [Related]
12. Reduced dose of post-transplantation cyclophosphamide compared to ATG for graft-versus-host disease prophylaxis in recipients of mismatched unrelated donor hematopoietic cell transplantation: a single-center study.
Soltermann Y; Heim D; Medinger M; Baldomero H; Halter JP; Gerull S; Arranto C; Passweg JR; Kleber M
Ann Hematol; 2019 Jun; 98(6):1485-1493. PubMed ID: 30915500
[TBL] [Abstract][Full Text] [Related]
13. Reduced-dose post-transplant cyclophosphamide plus low-dose post-transplant anti-thymocyte globulin as graft-versus-host disease prophylaxis with fludarabine-busulfan-cytarabine conditioning in haploidentical peripheral blood stem cell transplantation: A multicentre, randomized controlled clinical trial.
Zhang W; Gui R; Zu Y; Zhang B; Li Z; Zhang Y; Wang X; Guo S; Zhan X; Fu Y; Song Y; Zhou J
Br J Haematol; 2023 Jan; 200(2):210-221. PubMed ID: 36200642
[TBL] [Abstract][Full Text] [Related]
14. Low-dose post-transplant cyclophosphamide with low-dose antithymocyte globulin for prevention of graft-versus-host disease in first complete remission undergoing 10/10 HLA-matched unrelated donor peripheral blood stem cell transplants: a multicentre, randomized controlled trial.
Zu Y; Li Z; Gui R; Liu Y; Zhang Y; Yu F; Zhao H; Fu Y; Zhan X; Wang Z; Xing P; Wang X; Wang H; Zhou J; Song Y
Bone Marrow Transplant; 2022 Oct; 57(10):1573-1580. PubMed ID: 35840747
[TBL] [Abstract][Full Text] [Related]
15. Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT.
Spyridonidis A; Labopin M; Brissot E; Moiseev I; Cornelissen J; Choi G; Ciceri F; Vydra J; Reményi P; Rovira M; Meijer E; Labussière-Wallet H; Blaise D; van Gorkom G; Kröger N; Koc Y; Giebel S; Bazarbachi A; Savani B; Nagler A; Mohty M
Bone Marrow Transplant; 2022 Dec; 57(12):1774-1780. PubMed ID: 36071114
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donor.
Paviglianiti A; Ngoya M; Peña M; Boumendil A; Gülbas Z; Ciceri F; Bonifazi F; Russo D; Fegueux N; Stolzel F; Bulabois CE; Socié G; Forcade E; Solano C; Finel H; Robinson S; Glass B; Montoto S
Bone Marrow Transplant; 2024 May; 59(5):597-603. PubMed ID: 38331980
[TBL] [Abstract][Full Text] [Related]
17. Post-transplant cyclophosphamide versus anti-thymocyte globulin after reduced intensity peripheral blood allogeneic cell transplantation in recipients of matched sibling or 10/10 HLA matched unrelated donors: final analysis of a randomized, open-label, multicenter, phase 2 trial.
Brissot E; Labopin M; Labussière H; Fossard G; Chevallier P; Guillaume T; Yakoub-Agha I; Srour M; Bulabois CE; Huynh A; Chantepie S; Menard AL; Rubio MT; Ceballos P; Dulery R; Furst S; Malard F; Blaise D; Mohty M
Blood Cancer J; 2024 Feb; 14(1):31. PubMed ID: 38374026
[TBL] [Abstract][Full Text] [Related]
18. Anti-thymocyte Globulin and Post-Transplant Cyclophosphamide do not abrogate the inferior outcome risk conferred by human leukocyte antigen-A and -B mismatched donors.
Novitzky-Basso I; Remberger M; Chen C; Ellison C; Pasic I; Lam W; Law A; Gerbitz A; Viswabandya A; Lipton JH; Kim DD; Kumar R; Michelis FV; Mattsson J
Eur J Haematol; 2022 Apr; 108(4):288-297. PubMed ID: 34905239
[TBL] [Abstract][Full Text] [Related]
19. Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients.
Wang Y; Wu DP; Liu QF; Xu LP; Liu KY; Zhang XH; Yu WJ; Xu Y; Huang F; Huang XJ
J Hematol Oncol; 2019 Sep; 12(1):88. PubMed ID: 31481121
[TBL] [Abstract][Full Text] [Related]
20. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Giebel S; Labopin M; Salmenniemi U; Socié G; Bondarenko S; Blaise D; Kröger N; Vydra J; Grassi A; Bonifazi F; Czerw T; Anagnostopoulos A; Lioure B; Ruggeri A; Savani B; Spyridonidis A; Sanz J; Peric Z; Nagler A; Ciceri F; Mohty M
Cancer; 2023 Dec; 129(23):3735-3745. PubMed ID: 37658621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
